Low apoA-I is associated with insulin resistance in patients with impaired glucose tolerance: a cross-sectional study by unknown
RESEARCH Open Access
Low apoA-I is associated with insulin
resistance in patients with impaired
glucose tolerance: a cross-sectional study
Xiaomeng Feng , Xia Gao, Zhi Yao and Yuan Xu*
Abstract
Background: Low apolipoprotein A-I (apoA-I) is an independent risk factor for atherosclerotic cardiovascular diseases.
Insulin resistance predicts the progression of abnormal glucose metabolism, which is the main cause of atherosclerotic
cardiovascular disease. In this study, we assessed the potential association between apoA-I levels and insulin resistance
in patients with impaired glucose tolerance (IGT) and the possible link between apoA-I and IGT.
Methods: This study evaluated a cross-sectional study of 108 participants with impaired glucose tolerance (IGT group)
and 84 controls (control group). ApoA-I and clinical characteristics were measured, and a homeostasis model
assessment of insulin resistance (HOMA-IR) was calculated.
Results: The IGT group exhibited significantly lower apoA-I and higher HOMA-IR levels than the control group (apoA-I:
1.37 ± 0.36 vs 1.57 ± 0.39 g/L; HOMA-IR: 4.21 ± 1.56 vs 2.15 ± 0.99; P < 0.001 for both). ApoA-I was negatively correlated
with HOMA-IR in both the IGT and control groups (IGT group: r = −0.269, P = 0.005; control group: r = −0.262, P = 0.016).
Multiple stepwise regression analysis showed that low apoA-I levels (β = −1.470, P = 0.002) were independently
correlated with high HOMA-IR levels in the IGT group. Moreover, logistic regression analysis identified that low apoA-I
was an independent influencing factor for IGT (β = −1.170, OR = 0.310, P = 0.007).
Conclusions: ApoA-I is inversely associated with insulin resistance in patients with impaired glucose tolerance, and low
apoA-I is an independent risk factor for impaired glucose tolerance. These results indicate that apoA-I plays an
important role in regulating insulin sensitivity and glucose metabolism in patients with IGT.
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Background
Insulin resistance predicts the development of type 2
diabetes [1] and atherosclerotic cardiovascular disease
(ASCVD) [2] and begins to increase considerably before
the onset of diabetes. Impaired glucose tolerance (IGT),
which is characterized by high postprandial blood
glucose levels, causes the development of type 2 diabetes
[3] and ASCVD [4]. Postprandial blood glucose levels
are frequently associated with elevated insulin resistance,
which may have a more damaging effect on the vascula-
ture including the activation of inflammatory pathways,
increased oxidative stress, an extensive procoagulant
state, and abnormal vasomotion [5].
High-density lipoprotein cholesterol (HDL-C) is
involved in cardiovascular protection [6]. Apolipoprotein
A-I (apoA-I) is the major apolipoprotein constituent of
HDL-C [6]. Both HDL-C and apoA-I play important
roles in reverse cholesterol transport and exhibit
anti-atherogenic activities, including anti-thrombotic,
anti-oxidative, and anti-inflammatory activities, which
are independent of their reverse cholesterol transport ac-
tivities [7]. Based on the results of many epidemiological
studies, HDL-C has been considered an independent
negative risk factor for ASCVD; however, in the INTER-
HEART STUDY, apoA-I levels were shown to have a
stronger effect in preventing the development of
ASCVD than HDL-C levels [8]. This finding suggests
that it is necessary to focus not simply on decreases in
HDL-C levels but on the fact that decreases in apoA-I
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levels are important for the induction of ASCVD. More-
over, apoA-I has been documented to independently
promote insulin secretion and glucose uptake [9] and to
be negatively correlated with insulin resistance in
patients with type 2 diabetes [10].
Studies have shown that insulin secretion and islet
β-cell function are elevated several years before the
onset of diabetes and then decrease until the time of
diagnosis [11]. A compensatory period (i.e., a compensa-
tory increase in insulin production that is secondary to
high insulin resistance and the elevated secreting load of
islet β-cells with subtle changes in glucose levels) has
been identified before the onset of diabetes, and insulin
production decreases after the diagnosis of diabetes [11].
Insulin resistance might be considered to be responsible
for the increase in the secreting load of islet β-cells and
insulin secretion during the compensatory period. Fur-
thermore, reduced levels of apoA-I occur years before
the development of type 2 diabetes [12]. Therefore, it is
of interest to assess the possible association between
apoA-I and insulin resistance in patients with impaired
glucose tolerance and the potential correlation between
apoA-I and IGT. However, these associations have not
been well-characterized. In this study, we assessed the
possible association between apoA-I and insulin resist-
ance in patients with impaired glucose tolerance and the
link between apoA-I and the probability of being IGT.
Methods
Subjects
All participants (both genders, ranging in age from 30 to
70 years) were recruited from March 2015 to March 2016.
In total, 108 patients with impaired glucose tolerance
were recruited for this study from a group of outpatients
at the Department of Endocrinology, Beijing Chao-Yang
Hospital, Capital Medical University, Beijing, China.
Participants diagnosed with IGT as defined by the
American Diabetes Association criteria [13] were eligible
for the study. The following exclusion criteria for the
IGT group were applied: normal glucose tolerance,
impaired fasting glucose, and diabetes.
Eighty-four people were recruited to the control group
from the community and people undergoing routine
medical check-ups. None of these people were diagnosed
with prediabetes (including impaired glucose tolerance
and impaired fasting glucose) or diabetes.
Moreover, people with hypertension, coronary artery
disease, endocrine disease, systemic inflammatory
disease, infectious disease, cancer, liver or renal function
impairment, pregnancy or lactation were excluded from
both groups. People taking agents known to influence
glucose or insulin metabolism and/or people being
treated with lipid-lowering drugs were also excluded
from both groups.
The study protocol was approved by the Medicine and
Pharmacy Ethics Committee of Beijing Chao-Yang
Hospital, Capital Medical University. Written informed
consent was obtained from each participant.
Clinical and biochemical measurements
A standard questionnaire was used to collect informa-
tion about the participants’ health status and medica-
tions. Height and weight were measured without shoes
and in light clothing to the nearest 0.1 cm and 0.1 kg,
respectively, by the same trained group. Body mass index
(BMI) was calculated as weight (kg) / [height (m)]2.
Blood pressure was measured using a calibrated stand-
ard mercury sphygmomanometer. All readings were
measured from the non-dominant arm after a 5-min
resting period with the patients in the sitting position.
Fasting blood samples were collected in the morning
after an 8-h overnight fast. All patients underwent 75 g
oral glucose tolerance tests (OGTT). Blood samples
were collected at 0 min and 120 min following the
OGTT. Total cholesterol (TC), HDL-C, low-density
lipoprotein cholesterol (LDL-C), triglycerides (TG),
apoA-I, apolipoprotein B (apoB), fasting blood glucose
(FBG), 2-h postchallenge glucose (2hPG), glycated
hemoglobin (HbA1c) and fasting insulin (FINS) levels
were measured in the Central Laboratory of Beijing
Chao-Yang Hospital, Capital Medical University.
Serum insulin levels were determined by the electroche-
miluminescence method using an Elecsys-2010 Automatic
Electrochemical Immuno-analyser (Roche Corporation).
Blood glucose levels were measured using the hexokinase-
UV/NAD method (Olympus). Blood lipids were measured
as follows: TC levels were measured using the cholesterol
oxidase-HDAOS method (Wako); TG levels were mea-
sured using the GPO-HDAOS glycerol blanking method
(Wako); HDL-C levels were measured using the immu-
noinhibition (direct) method (Wako); LDL-C levels were
measured using the selective protection enzymatic (direct)
method (Wako), and apoA-I and apoB levels were
measured using the immunoturbidimetric method
(Olympus). Serum glucose and lipid levels were analysed
using an Olympus AU5400 Automatic Biochemistry
Analyser (Olympus Corp, Japan). HbA1c analysis was per-
formed by high-performance liquid chromatography using
a HLC-723 G8 Automatic Analyser (Tosoh Corp, Japan).
Insulin resistance was measured using the following
method: homeostasis model assessment of insulin resist-
ance (HOMA-IR) = FINS (mIU/L) * FBG (mmol/L) / 22.5.
Statistical analysis
All analyses were performed using Statistical Package for
Social Sciences version 19.0 (SPSS, Inc., Chicago, IL,
USA). The normality of the data distribution was verified
using the Kolmogorov-Smirnov test. Normally distributed
Feng et al. Lipids in Health and Disease  (2017) 16:69 Page 2 of 7
data were expressed as the means ± standard deviations.
Non-normally distributed data were expressed as medians
with 25th and 75th percentiles. Comparisons of the clin-
ical and biochemical markers between the two groups
were performed using the independent sample t test and
the Mann-Whitney U Test. Proportions were analysed
using the chi-squared test. Association was tested using
Pearson’s correlation coefficient analyses, multiple step-
wise regression analyses, and logistic regression analysis.
In all statistical tests, P values < 0.05 were considered
significant, and all tests were two-sided.
Results
Clinical characteristics of individuals in the IGT and
control groups
The clinical characteristics of the participants are sum-
marized in Table 1. The participants in both groups were
similar in sex, age, systolic blood pressure (SBP),
diastolic blood pressure (DBP), TC, and apoA-I/HDL-
C (P > 0.05 for all). The levels of BMI (P < 0.001),
LDL-C (P = 0.024), TG (P < 0.001), apoB (P = 0.030),
FBG (P < 0.001), 2hPG (P < 0.001), HbA1c (P < 0.001)
and FINS (P < 0.001) were higher and the levels of
HDL-C (P < 0.001) were lower in the IGT group than
in the control group.
Levels of apoA-I in the IGT and control groups
The levels of apoA-I were significantly lower in the IGT
group than those in the control group (1.37 ± 0.36 vs
1.57 ± 0.39 g/L, P < 0.001) (Fig. 1).
Values of HOMA-IR in the IGT and control groups
The values of HOMA-IR were significantly higher in the
IGT group than those in the control group (4.21 ± 1.56
vs 2.15 ± 0.99, P < 0.001) (Fig. 2).
Correlation between apoA-I and HOMA-IR
ApoA-I was negatively correlated with HOMA-IR in
both the IGT and control groups (IGT group: r = −0.269,
95% confidence interval: −0.419 to −0.105, P = 0.005,
(Fig. 3a); control group: r = −0.262, 95% confidence
interval: −0.426 to −0.082, P = 0.016; Fig. 3b).
Multiple regression analyses of anthropometric
parameters and lipid profile associated with HOMA-IR
Multiple stepwise regression analyses were performed to
determine which parameters were independently associ-
ated with HOMA-IR in the two groups. The results
showed that after adjusting for anthropometric parame-
ters and lipid profile, the increased TG levels (P = 0.002)
and the decreased apoA-I levels (P = 0.002) were inde-
pendently related to high HOMA-IR in the IGT group
(Table 2) and the elevated BMI levels (P = 0.010) were
independently associated with high HOMA-IR in the
control group (Table 3). The model in the IGT group
had an adjusted R-squared value of 0.174 (F = 9.855 and P
< 0.001), and the model in the control group had an ad-
justed R-squared value of 0.069 (F = 7.039 and P = 0.010).
Logistic regression analysis of the anthropometric
parameters and lipid profile associated with IGT
The adjusted results of a logistic regression analysis of
the associations between the anthropometric parameters
and the lipid profile and IGT are shown in Table 4.
ApoA-I and BMI were independently associated with






Sex (M/F) 65/43 44/40 0.279
Age (years) 57.31 ± 7.21 56.83 ± 7.55 0.651
BMI (kg/m2) 26.43 ± 4.83 24.26 ± 3.44 0.001
SBP (mmHg) 128.11 ± 6.86 126.46 ± 6.89 0.101
DBP (mmHg) 75.62 ± 6.50 74.14 ± 7.38 0.142
TC (mmol/L) 5.15 ± 1.06 4.92 ± 0.91 0.109
HDL-C (mmol/L) 1.34 ± 0.27 1.58 ± 0.37 <0.001
LDL-C (mmol/L) 3.10 ± 0.74 2.85 ± 0.75 0.024
TG (mmol/L) 2.37 (1.99, 2.79) 1.09 (0.71, 1.48) <0.001
ApoA-I (g/L) 1.37 ± 0.36 1.57 ± 0.39 <0.001
ApoB (g/L) 0.97 ± 0.22 0.90 ± 0.23 0.030
ApoA-I/HDL-C 0.99 (0.91, 1.10) 0.99 (0.85, 1.11) 0.821
FBG (mmol/L) 6.30 (5.60, 6.98) 5.58 (5.24, 5.82) <0.001
2hPG (mmol/L) 9.30 (8.63, 9.80) 6.50 (6.08, 6.73) <0.001
HbA1c (%) 6.30 (6.00, 6.40) 5.90 (5.60, 6.10) <0.001
FINS (mIU/L) 15.70 (10.80, 18.30) 8.17 (5.39, 11.97) <0.001
HOMA-IR 4.21 ± 1.56 2.15 ± 0.99 <0.001
IGT group, patientswith impaired glucose tolerance; Control group, control
subjects; BMI body mass index, SBP systolic blood pressure, DBP diastolic blood
pressure, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C
low-density lipoprotein cholesterol, TG triglycerides, apoA-I apolipoprotein A-I,
apoB apolipoprotein B, FBG fasting blood glucose, 2hPG 2-h postchallenge
glucose, HbA1c glycated hemoglobin, FINS fasting insulin, HOMA-IR homeostasis
model assessment of insulin resistance
Fig. 1 Apolipoprotein A-I (apoA-I) levels measured in the study
participants. The values are expressed as the means ± standard
deviations. IGT group, patients with impaired glucose tolerance
(n = 108); Control group, control subjects (n = 84)
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IGT: apoA-I (P = 0.007) was inversely associated and
BMI (P = 0.008) was positively associated with IGT.
Discussion
In the present study, patients with impaired glucose tol-
erance presented significantly lower levels of HDL-C
and apoA-I than the controls. HDL-C is an anti-
atherogenic lipoprotein. ApoA-I is a major functional
component of HDL-C and is extensively involved in the
cardiovascular protective effects of HDL-C [6]. HDL-C
and apoA-I transport cholesterol from cells into periph-
eral tissues, reduce oxidative stress, suppress inflamma-
tory pathways [7], neutralize procoagulant properties of
anionic phospholipids and attenuate the excessive stimu-
lation of blood coagulation [14], and prevent LDL-C oxi-
dation by removing oxidized phospholipids from LDL-C
and from arterial wall cells [15]. Therefore, the adminis-
tration of apoA-I has been proposed for use as a poten-
tial therapeutic strategy to protect the cardiovascular
system [16, 17]. Transgenic mice over-expressing apoA-I
exhibit high HDL-C levels and low vascular lesions [18].
Laboratory studies have shown that apoA-I reduces the
lipid and macrophage content of arteries and decreases
lesion formation in mouse and rabbit models of
atherosclerosis [19, 20]. ApoA-I infusion has been docu-
mented to reduce atheroma volume in patients with cor-
onary atherosclerosis compared with baseline [21]. In
addition, pharmacological strategies that target apoA-I,
including the upregulation of its production with the
bromodomain and extraterminal protein inhibitor RVX-
208, the development of short peptide sequences that
mimic its action, and its administration as a component
of reconstituted HDL-C (containing apoA-I as its only
protein and a phospholipid as its only lipid) have benefi-
cial effects on inflammatory factors that are known to be
involved in atherosclerosis and plaque stability [16, 22].
However, it has been demonstrated that TaqIB poly-
morphism in the cholesterol ester transfer protein gene
has a significant impact on HDL-C levels, while the
effect of a 75G/A polymorphism in the apoA-I gene was
not significant [23]. Although several clinical studies
have indicated that low apoA-I levels are an independent
risk factor for ASCVD [24–26], the underlying mechan-
ism linking apoA-I with the delay of atherosclerotic
plaque progression remains unknown. The results of
various studies have supported the notion that apoA-I
protection against cardiovascular events might at least in
part be mediated through improving insulin sensitivity.
In our study, the IGT group exhibited higher
HOMA-IR and FINS than the control group, a finding
Fig. 2 Homeostasis model assessment of insulin resistance (HOMA-IR)
of the study participants. The values are expressed as the means ±
standard deviations. IGT group, patients with impaired glucose
tolerance (n = 108); Control group, control subjects (n = 84)
a b
Fig. 3 Correlations between apoA-I levels and HOMR-IR in the IGT group (a) and in the control group (b). ApoA-I, apolipoprotein A-I; HOMR-IR,
homeostasis model assessment of insulin resistance; IGT group, patients with impaired glucose tolerance (n = 108); Control group, control
subjects (n = 84)
Table 2 Multiple regression of parameters associated with
HOMA-IR in patients with IGT (n = 108)
Parameters β SE Standardized β 95% CI P value
Constant 4.788 0.752 3.282 ~ 6.274 <0.001
TG (mmol/L) 0.540 0.166 0.323 0.209 ~ 0.870 0.002
ApoA-I (g/L) −1.470 0.456 −0.319 −2.382 ~ −0.558 0.002
HOMA-IR homeostasis model assessment of insulin resistance, IGT impaired
glucose tolerance; SE standard error, CI confidence interval, TG triglycerides,
apoA-I apolipoprotein A-I. Adjustment for age, sex, body mass index (BMI),
systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol
(TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein
cholesterol (LDL-C), TG, apoA-I, and apolipoprotein B (apoB)
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that might support the notion that IGT promotes the
progression of ASCVD due to insulin resistance and
hyperinsulinemia. Hyperinsulinemia caused by insulin
resistance directly stimulates the in vitro migration of
neutrophils and monocytes in response to chemokines
that are secreted by atherosclerotic plaques [27]. Hyper-
insulinemia might promote atherosclerotic plaque
necrosis by accelerating macrophage death [28]. In
particular, hyperinsulinemia induces the production of
matrix metalloproteinase-9 (MMP-9), which provokes
plaque instability and rupture [29]. Pharmacological and
behavioural treatments to reduce insulin resistance have
been shown to repress MMP-9 secretion [30]. Moreover,
insulin resistance might intensify a serious atherothrom-
botic state by elevating platelet resistance to antiaggre-
gating agents [31] and accelerating the production of
procoagulatory factors [30]. Thus, the evidence strongly
supports an emerging role of insulin resistance in plaque
instability and rupture.
The present cross-sectional study identified the inverse
association between apoA-I and insulin resistance in
patients with impaired glucose tolerance; this finding is
similar to that of a previous study in patients with type 2
diabetes [10]. Recent studies have reported that HDL-C
and apoA-I improve pancreatic β-cell function. In
human islet cell culture and animal studies, exogenous
HDL-C has been found to attenuate the inflammation-
induced apoptosis of pancreatic β-cells [9]. The infusion
of exogenous reconstituted HDL-C potentiated both
insulin secretion and skeletal muscle glucose uptake in a
small trial with type 2 diabetic patients [32]. ApoA-I
treatment was found to increase glucose-stimulated
insulin secretion in mice that were fed a high-fat diet
[33, 34] and ameliorated β-cell dysfunction by inhibiting
β-cell apoptosis [9, 35]. The favourable effects of apoA-I
on improving insulin sensitivity have been further inves-
tigated in human skeletal muscle cells and adipocytes, in
which both HDL-C and apoA-I promoted glucose
uptake independently of insulin stimulation [32, 36, 37].
The mechanism connecting low apoA-I to high insulin
resistance has been unclear. However, recent studies
have supported the hypothesis that apoA-I might exert
beneficial effects on ameliorating insulin resistance
through different pathways. Recently, a new concept has
been accepted suggesting that insulin resistance might
primarily start in the vascular endothelium [38]. Endo-
thelial nitric oxide synthase (eNOS) dysfunction might
reduce microcirculatory blood flow and decrease the de-
livery of insulin within hormone-sensitive organs.
Insulin-mediated glucose uptake has been found to be
inhibited in eNOS−/− mice compared with wild type
mice [39]. Thus, the restoration of eNOS function can
decrease insulin resistance [40]. It has been proposed
that apoA-I is fundamental for the process by which
HDL-C activates eNOS [41]. ApoA-I binding to the
scavenger receptor-BI is required for the HDL-C activa-
tion of eNOS [41]. Furthermore, apoA-I is responsible
for the effects of endothelial cell migration. ApoA-I has
been proven to prevent endothelial apoptosis that is
induced by oxidized-LDL-C [42] and tumour necrosis
factor α [43]. It has been suggested that inflammation
might be crucial for the development of insulin resist-
ance and β-cell dysfunction [44]. Inflammatory cytokines
and acute-phase reactants are positively correlated with
insulin resistance in patients with metabolic syndrome
[45]. The anti-inflammatory effects of apoA-I have been
observed in both in vitro and in vivo studies. Reconsti-
tuted HDL-C has been found to inhibit the expression
of vascular cell adhesion molecule-1, intercellular adhe-
sion molecule-1, and E-selection in activated endothelial
cells growing in tissue culture [46]. In macrophages,
apoA-I has been shown to prevent inflammation by
suppressing cluster of differentiation 40 L-induced acti-
vation of nuclear factor-κ-gene binding [47]. A recent
study has reported that changes in apoA-I but not in
HDL-C are negatively correlated with changes in high-
sensitivity C-reactive protein (hs-CRP), which is a
predictor of the development of cardiovascular events
[48]. The increase of apoA-I that follows pitavastatin
treatment is an independent predictor of decreased
levels of hs-CRP [49]. Hence, apoA-I might decrease
insulin resistance by improving vascular endothelium
function and inhibiting inflammation.
Therefore, we speculated that decreased insulin resist-
ance due to increased apoA-I levels may partially explain
the protective effects of apoA-I on the cardiovascular
Table 3 Multiple regression of parameters associated with
HOMA-IR in controls (n = 84)
Parameters β SE Standardized β 95% CI P value
Constant 0.167 0.754 −1.332 ~ 1.667 0.825
BMI (kg/m2) 0.082 0.031 0.283 0.020 ~ 0.143 0.010
HOMA-IR homeostasis model assessment of insulin resistance, SE standard
error, CI confidence interval, BMI body mass index. Adjustment for age, sex,
BMI, systolic blood pressure (SBP), diastolic blood pressure (DBP), total
cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density
lipoprotein cholesterol (LDL-C), triglycerides (TG), apolipoprotein A-I (apoA-I),
and apolipoprotein B (apoB)
Table 4 Logistic regression of anthropometric parameters and
lipid profile associated with IGT (n = 182)
β SE OR 95% CI P value
Constant −0.784 1.296 0.457 0.546
ApoA-I (g/L) −1.170 0.433 0.310 0.133 ~ 0.725 0.007
BMI (kg/m2) 0.109 0.041 1.115 1.029 ~ 1.209 0.008
IGT impaired glucose tolerance, SE standard error, OR odds ratio, CI confidence
interval, apoA-I apolipoprotein A-I, BMI body mass index. Adjustment for age,
sex, BMI, systolic blood pressure (SBP), low-density lipoprotein cholesterol
(LDL-C), and apoA-I
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system that have been observed in clinical trials [24–26].
Increased insulin sensitivity that is mediated through
high apoA-I levels favours the transport of glucose from
the circulation into tissues and has potential clinical
relevance in terms of reducing cardiovascular complica-
tions by removing excess glucose from the circulation
and in providing adequate glucose to tissues for energy
production, particularly in the context of cardiovascular
events [50].
Importantly, the finding that apoA-I is negatively
related to insulin resistance might partially explain our
result that low apoA-I is an independent factor influen-
cing impaired glucose tolerance. Recent studies have
documented that insulin resistance is a major determin-
ant of the development and progression of abnormal
glucose metabolism [1]. Increased insulin resistance
drives a compensatory increase in insulin secretion dur-
ing the early stage of abnormal glucose metabolism [11].
However, the chronic overload of islet β-cells will lead to
the deterioration of β-cell function, if sustained. When
insulin secretion is insufficient and blood glucose levels
rise, IGT and diabetes ultimately become overt. There-
fore, IGT might be the result of chronic exposure to
severe insulin resistance, which is at least partly induced
by low apoA-I levels and which portends the earlier ini-
tiation of hyperglycaemia [10]. Therefore, low apoA-I
levels might be an independent risk factor for IGT.
The limitations of our study are as follows. First, our
study population was limited to Chinese individuals.
Therefore, our findings may not be directly applicable to
other populations. Second, our sample size was small;
thus, our findings were not powerful enough to account
for potentially confounding factors in our analyses, and
our results might have been improperly influenced by
some outliers due to the small sample size. Third, the
cross-sectional design of the present study does not allow
us to determine the existence of a causal relationship but
rather provides evidence for the association between low
apoA-I levels and high insulin resistance in patients with
impaired glucose tolerance. Our study certainly raises
credible hypotheses that remain be confirmed and
extended by future prospective cohort and mechanistic
studies. Fourth, our study estimated insulin resistance
based on HOMA-IR rather than by precise methods, such
as the hyperinsulinemic euglycaemic clamp technique.
Conclusions
Here, we report a negative association between apoA-I
and insulin resistance in patients with impaired glucose
tolerance and demonstrate a correlation between low
apoA-I levels and impaired glucose tolerance. These
results indicate that apoA-I plays an important role in
regulating insulin sensitivity and glucose metabolism in
patients with impaired glucose tolerance.
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